← Back to Screener
Theriva Biologics, Inc. (TOVX)
Price$0.26
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-13.37%
Price vs S&P 500 (4W)-27.90%
VGM Score49.95
Market Capitalization$11.71M
All Metrics
Book Value / Share (Quarterly)$0.34
P/TBV (Annual)2.85x
Cash Flow / Share (Quarterly)$-0.31
Price vs S&P 500 (YTD)13.13%
Gross Margin (TTM)71.52%
Net Profit Margin (TTM)-681.33%
EPS (TTM)$-2.50
10-Day Avg Trading Volume1.36M
EPS Excl Extra (TTM)$-2.50
EPS (Annual)$-1.96
ROI (Annual)-138.74%
Gross Margin (Annual)-20.00%
Net Profit Margin (5Y Avg)-18442.92%
Cash / Share (Quarterly)$0.31
ROA (Last FY)-62.08%
EBITD / Share (TTM)$-1.00
ROE (5Y Avg)-78.60%
Operating Margin (TTM)-709.00%
Cash Flow / Share (Annual)$-0.47
P/B Ratio0.76x
P/B Ratio (Quarterly)0.58x
Net Income / Employee (Annual)$-1,582,600
Net Interest Coverage (TTM)-32.17x
ROA (TTM)-59.96%
EPS Incl Extra (Annual)$-1.96
Current Ratio (Annual)1.74x
Quick Ratio (Quarterly)1.58x
3-Month Avg Trading Volume18.66M
52-Week Price Return-45.82%
Revenue / Employee (TTM)$20,000
Tangible BV / Share (Quarterly)$0.61
P/S Ratio (Annual)4.49x
Asset Turnover (Annual)0.64x
52-Week High$0.86
Operating Margin (5Y Avg)-17385.37%
EPS Excl Extra (Annual)$-1.96
CapEx CAGR (5Y)28.47%
Tangible BV CAGR (5Y)35.96%
26-Week Price Return-5.45%
Quick Ratio (Annual)1.64x
13-Week Price Return38.39%
Total Debt / Equity (Annual)0.11x
Current Ratio (Quarterly)1.63x
Enterprise Value$-1.06M
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)-33.97%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-45.98%
Cash / Share (Annual)$0.37
3-Month Return Std Dev159.14%
Net Income / Employee (TTM)$-1,430,600
ROE (Last FY)-154.32%
Net Interest Coverage (Annual)-212.50x
EPS Basic Excl Extra (Annual)$-1.96
Receivables Turnover (TTM)17.08x
Total Debt / Equity (Quarterly)0.11x
EPS Incl Extra (TTM)$-2.50
Receivables Turnover (Annual)0.00x
ROI (TTM)-156.24%
P/S Ratio (TTM)39.04x
Pretax Margin (5Y Avg)-18439.01%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.61
Price vs S&P 500 (52W)-70.18%
Year-to-Date Return21.29%
5-Day Price Return-9.50%
EPS Normalized (Annual)$-1.96
ROA (5Y Avg)-43.11%
Net Profit Margin (Annual)-65.52%
Month-to-Date Return-10.08%
Cash Flow / Share (TTM)$-1.16
EBITD / Share (Annual)$-1.97
Operating Margin (Annual)-45.98%
LT Debt / Equity (Annual)0.11x
ROI (5Y Avg)-75.18%
LT Debt / Equity (Quarterly)0.11x
EPS Basic Excl Extra (TTM)$-2.50
P/TBV (Quarterly)2.85x
P/B Ratio (Annual)0.46x
Pretax Margin (TTM)-681.33%
Book Value / Share (Annual)$0.43
Price vs S&P 500 (13W)30.14%
Beta1.11x
Revenue / Share (TTM)$0.01
ROE (TTM)-178.29%
52-Week Low$0.16
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.05est. -0.05
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.00
4.00
4.13
4.13
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TOVXTheriva Biologics, Inc. | — | — | C | $0.26 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Theriva Biologics is a clinical-stage biopharmaceutical company developing oncolytic adenovirus therapies for cancers with significant unmet medical needs. Its lead program, VCN-01, breaks down tumor stroma to enhance viral penetration, while preclinical program VCN-11 employs proprietary Albumin Shield Technology to protect oncolytic viruses from immune system inactivation during systemic delivery.